Aurobindo completes acquisition of Actavis' commercial ops in western Europe

Agreement to acquire operations of Ireland-based Actavis, a global, integrated speciality pharmaceutical company, was announced in January 2014

Hyderabad-based Aurobindo Pharma Limited on Tuesday stated it had completed the acquisition of certain commercial operations of NYSE-listed Actavis plc in western Europe.  

The agreement to acquire the operations of Ireland-based Actavis, a global, integrated speciality pharmaceutical company, was announced in January 2014.

According to a communique to stock exchanges, Aurobindo has acquired personnel, commercial infrastructure, products, marketing authorisations and dossier licence rights in seven European countries. Actavis and Aurobindo have also entered into a long-term commercial and supply arrangement.  

Aurobindo now intends to combine the strength of both enterprises in these markets and to identify and maximise all opportunities to improve performance.

Senior vice president of the company’s European operations, Muralidharan, said the acquisition  would make Aurobindo one of the leading Indian pharmaceutical companies in Europe.

It “will enable Aurobindo to achieve critical mass in western Europe with a top 10 position in several key markets,” he added.